A new study identifies how the molecule, called ApoM, can clear harmful cholesterol deposits linked to macular degeneration ...

Two examples of FDA-approved intracameral implants are Durysta (Allergan) and iDoseTR (Glaukos), both of which provide ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral ...

Yesafili is a VEGF inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), ...

Berlin: Bayer has received approval from the European Commission (EC) for a label extension in the European Union (EU) for ...

The PHOENIX study is a 24-month, randomized, double-masked, placebo-controlled, multicenter, pivotal Phase 3 trial. The study is ongoing across sites in the United States, the United Kingdom, France, ...

Landmark partnership will democratize access to critical eye treatment for millions facing preventable blindness from ...

NHS England has published updated medical retinal treatment pathway recommendations for wet age-related macular degeneration (wAMD), with pathways for diabetic macular oedema (DMO) and retinal vein ...

Career focused on driving business growth and developing an integrated commercial strategy to deliver results ...

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME: Berlin Saturday, June 28, 2025, 09:00 Hrs [IST] The Eur ...

Aldeyra's Reproxalap progresses towards FDA approval, with a potential $100M AbbVie deal. There’s still upside potential, ...